[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2019003298A - Proteinas de union recombinantes y sus usos. - Google Patents

Proteinas de union recombinantes y sus usos.

Info

Publication number
MX2019003298A
MX2019003298A MX2019003298A MX2019003298A MX2019003298A MX 2019003298 A MX2019003298 A MX 2019003298A MX 2019003298 A MX2019003298 A MX 2019003298A MX 2019003298 A MX2019003298 A MX 2019003298A MX 2019003298 A MX2019003298 A MX 2019003298A
Authority
MX
Mexico
Prior art keywords
binding proteins
recombinant binding
nucleic acids
recombinant
pharmaceutical compositions
Prior art date
Application number
MX2019003298A
Other languages
English (en)
Inventor
Fiedler Ulrike
DOLADO Ignacio
Metz Clara
Maria STROBEL Heike
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of MX2019003298A publication Critical patent/MX2019003298A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se desvelan nuevas proteínas de unión recombinantes, que comprenden dominios diseñados con repeticiones de anquirina con especificidad de unión para el HER2, y que comprenden dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina, así como los ácidos nucleicos que codifican dichas proteínas de unión recombinantes, composiciones farmacéuticas que comprenden dichas proteínas de unión recombinantes o ácidos nucleicos y el uso de dichas proteínas de unión recombinantes, ácidos nucleicos o composiciones farmacéuticas en el tratamiento de enfermedades.
MX2019003298A 2016-09-22 2017-09-20 Proteinas de union recombinantes y sus usos. MX2019003298A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16190221 2016-09-22
PCT/EP2017/073768 WO2018054971A1 (en) 2016-09-22 2017-09-20 Recombinant binding proteins and their use

Publications (1)

Publication Number Publication Date
MX2019003298A true MX2019003298A (es) 2019-09-26

Family

ID=57046984

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003298A MX2019003298A (es) 2016-09-22 2017-09-20 Proteinas de union recombinantes y sus usos.

Country Status (20)

Country Link
US (2) US10717772B2 (es)
EP (1) EP3515933B9 (es)
JP (1) JP6976335B2 (es)
KR (1) KR102270315B1 (es)
CN (1) CN109790206A (es)
AR (1) AR109680A1 (es)
AU (1) AU2017331329B2 (es)
BR (1) BR112019005587A2 (es)
CA (1) CA3036301C (es)
CL (1) CL2019000729A1 (es)
CO (1) CO2019002609A2 (es)
ES (1) ES2953516T3 (es)
IL (1) IL265489B (es)
MX (1) MX2019003298A (es)
MY (1) MY196882A (es)
NZ (1) NZ751689A (es)
PH (1) PH12019500596A1 (es)
SA (1) SA519401369B1 (es)
WO (1) WO2018054971A1 (es)
ZA (1) ZA201901592B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114222757A (zh) * 2019-06-04 2022-03-22 分子伴侣公司 重组4-1bb结合蛋白及其用途
BR112021024237A2 (pt) 2019-06-04 2022-04-19 Molecular Partners Ag Domínio de repetição de anquirina projetado com estabilidade aprimorada
SG11202112921VA (en) 2019-06-04 2021-12-30 Molecular Partners Ag Multispecific proteins
AU2020286600A1 (en) * 2019-06-04 2021-12-23 Molecular Partners Ag Recombinant FAP binding proteins and their use
KR20220113491A (ko) 2019-12-11 2022-08-12 몰리큘라 파트너스 아게 재조합 펩티드-mhc 복합체 결합 단백질 및 이의 생성 및 용도
EP4146691A1 (en) 2020-05-06 2023-03-15 Molecular Partners AG Novel ankyrin repeat binding proteins and their uses
CA3178478A1 (en) * 2020-05-14 2021-11-18 Valerie Perrine Calabro Recombinant cd40 binding proteins and their use
CA3178785A1 (en) 2020-05-14 2021-11-18 Nicolo RIGAMONTI Multispecific proteins
WO2022130300A1 (en) 2020-12-16 2022-06-23 Molecular Partners Ag Novel slow-release prodrugs
AU2022234894A1 (en) 2021-03-09 2023-10-05 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers
WO2022190018A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based cd123 engagers
US20240317852A1 (en) 2021-03-09 2024-09-26 Molecular Partners Ag Novel darpin based cd33 engagers
JP2024509890A (ja) 2021-03-09 2024-03-05 モレキュラー パートナーズ アクチェンゲゼルシャフト プロテアーゼ切断可能なプロドラッグ
CA3239407A1 (en) 2021-12-14 2023-06-22 Simon FONTAINE Designed repeat domains with dual binding specificity and their use
US20240228545A9 (en) 2022-08-01 2024-07-11 Molecular Partners Ag Charge modified designed repeat domains and their use
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
US20240368250A1 (en) 2023-02-17 2024-11-07 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
WO2024179981A1 (en) 2023-02-27 2024-09-06 Molecular Partners Ag Darpins for use in reducing renal accumulation of drugs

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
US7417130B2 (en) 2000-09-08 2008-08-26 University Of Zurich Collection of repeat proteins comprising repeat modules
WO2003018611A2 (en) * 2001-08-24 2003-03-06 University Of Victoria Innovation And Development Corporation Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
NZ591733A (en) 2004-11-12 2012-10-26 Bayer Schering Pharma Ag Recombinant newcastle disease virus comprising a transgene encoding a fusion protein comprising a binding domain and a heterologous domain comprising an enzyme
PL1902131T3 (pl) 2005-07-08 2010-05-31 Univ Zuerich Prezentacja fagowa z zastosowaniem kotranslacyjnej translokacji polipeptydów fuzyjnych
US9365629B2 (en) 2007-09-24 2016-06-14 University Of Zurich Designed armadillo repeat proteins
CA2706200A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Immunoglobulin constructs comprising multiple single variable domains and an fc portion
EP3785735A1 (en) 2008-11-03 2021-03-03 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
CN113278077A (zh) 2010-11-26 2021-08-20 分子组合公司 设计的与血清白蛋白结合的重复蛋白
WO2012149439A2 (en) 2011-04-29 2012-11-01 Janssen Biotech, Inc. Il4/il13 binding repeat proteins and uses
CA2877584A1 (en) 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
AU2013331763B2 (en) * 2012-10-15 2018-02-15 Universitat Zurich Bispecific HER2 ligands for cancer therapy
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
CN105209483B (zh) 2013-05-31 2021-07-27 分子组合公司 与肝细胞生长因子结合的设计锚蛋白重复蛋白
AU2016240220B2 (en) 2015-04-02 2019-11-21 Molecular Partners Ag Designed ankyrin repeat domains with binding specificity for serum albumin

Also Published As

Publication number Publication date
CA3036301A1 (en) 2018-03-29
WO2018054971A1 (en) 2018-03-29
EP3515933B1 (en) 2023-06-07
CN109790206A (zh) 2019-05-21
PH12019500596A1 (en) 2019-07-29
EP3515933B9 (en) 2023-08-16
ZA201901592B (en) 2021-04-28
CO2019002609A2 (es) 2019-05-31
AU2017331329A1 (en) 2019-04-04
EP3515933C0 (en) 2023-06-07
AU2017331329B2 (en) 2020-10-29
IL265489A (en) 2019-05-30
CA3036301C (en) 2021-04-20
IL265489B (en) 2021-07-29
RU2019111628A (ru) 2020-10-19
CL2019000729A1 (es) 2019-06-14
NZ751689A (en) 2021-07-30
JP2019531093A (ja) 2019-10-31
ES2953516T3 (es) 2023-11-14
MY196882A (en) 2023-05-08
BR112019005587A2 (pt) 2019-06-11
AR109680A1 (es) 2019-01-09
SA519401369B1 (ar) 2022-12-22
RU2019111628A3 (es) 2020-10-30
US10717772B2 (en) 2020-07-21
JP6976335B2 (ja) 2021-12-08
US20180155402A1 (en) 2018-06-07
US20210130420A1 (en) 2021-05-06
KR102270315B1 (ko) 2021-06-29
KR20190050802A (ko) 2019-05-13
EP3515933A1 (en) 2019-07-31

Similar Documents

Publication Publication Date Title
PH12019500596A1 (en) Recombinant binding proteins and their use
SA517390092B1 (ar) مجالات تكرار أنكيرين مصمَّمة ذات نوعية ربط تجاه ألبومين مصل
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
PH12020551907A1 (en) Antagonizing cd73 antibody
MX2022007122A (es) Dominios de repetición de anquirina diseñados con residuos de superficie alterados.
WO2015109124A3 (en) Immunomodulatory agents
MX2024003743A (es) Inmunoglobulinas de union a agrecano.
MX2024005946A (es) Polipeptidos que se unen al componente del complemento c5 o albumina serica y proteinas de fusion de los mismos.
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
MX2021014649A (es) Dominio de repetición de anquirina diseñado con estabilidad mejorada.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
MX2020009507A (es) Anticuerpos de dominio individual que se unen a la neurotoxina del tetanos.
WO2016040767A3 (en) Chrdl-1 epitopes and antibodies

Legal Events

Date Code Title Description
FG Grant or registration